Literature DB >> 2015290

The active site of deoxyhypusyl hydroxylase: use of catecholpeptides and their component chelator and peptide moieties as molecular probes.

A Abbruzzese1, H M Hanauske-Abel, M H Park, S Henke, J E Folk.   

Abstract

The final step of hypusine formation in the eukaryotic translation initiation factor 4D (eIF-4D) is mediated by the enzyme deoxyhypusyl hydroxylase. In an effort to find specific inhibitors for this enzyme, we have studied the effects of two catecholpeptides, N alpha-acetyl-N delta-(3,4-dihydroxybenzoyl)-L-Orn-L-Pro-Gly (compound I) and N alpha-acetyl-N delta-(2,3-dihydroxybenzoyl)-L-Orn-L-Pro-Gly (compound II). Their structures were designed for anchorage to the enzyme s active site, utilizing the catechol-mediated chelation of a putative, enzyme-bound metal ion. Both compounds were found to strongly inhibit hypusine formation in vitro. Compound I was about seven times more potent than compound II, whereas the component peptide itself showed no intrinsic inhibitory activity even at concentrations as high as 1 mM. When used in conjugation with a chelating catechol moiety, however, it gave a 17- and an 8-fold enhancement of the half-maximal inhibition mediated by the chelating moieties per se, i.e. the 3,4- and the 2,3-dihydroxybenzoyl esters, respectively. The mode of inhibition by compound I was competitive with respect to the unhydroxylated precursor of eIF-4D and showed a Ki value of 32 microM +/- 3.4 microM. These catecholpeptides are the most efficient peptide antagonists of deoxyhypusyl hydroxylase known at present. They allow an assessment of the enzyme's active site organization and provide the first experimental evidence that a metal ion constitutes an integral part of its catalytic center.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015290     DOI: 10.1016/0167-4838(91)90053-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer.

Authors:  Shima Nakanishi; John L Cleveland
Journal:  Amino Acids       Date:  2016-06-29       Impact factor: 3.520

2.  The polyamine-derived amino acid hypusine: its post-translational formation in eIF-5A and its role in cell proliferation.

Authors:  M H Park; Y A Joe; K R Kang; Y B Lee; E C Wolff
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

3.  Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.

Authors:  M Caraglia; A Passeggio; S Beninati; A Leardi; L Nicolini; S Improta; A Pinto; A R Bianco; P Tagliaferri; A Abbruzzese
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

4.  Piperidones with activity against Plasmodium falciparum.

Authors:  Michael Saeftel; Ramadan Salem Sarite; Tujo Njuguna; Ulrike Holzgrabe; Daniela Ulmer; Achim Hoerauf; Annette Kaiser
Journal:  Parasitol Res       Date:  2006-03-21       Impact factor: 2.289

5.  The role of hypusine depletion in cytostasis induced by S-adenosyl-L-methionine decarboxylase inhibition: new evidence provided by 1-methylspermidine and 1,12-dimethylspermine.

Authors:  T L Byers; J R Lakanen; J K Coward; A E Pegg
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

6.  Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation.

Authors:  Elisabeth Mémin; Mainul Hoque; Mohit R Jain; Debra S Heller; Hong Li; Bernadette Cracchiolo; Hartmut M Hanauske-Abel; Tsafi Pe'ery; Michael B Mathews
Journal:  Cancer Res       Date:  2013-11-12       Impact factor: 12.701

7.  Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries.

Authors:  T A McCaffrey; K B Pomerantz; T A Sanborn; A M Spokojny; B Du; M H Park; J E Folk; A Lamberg; K I Kivirikko; D J Falcone
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

9.  Drug-induced reactivation of apoptosis abrogates HIV-1 infection.

Authors:  Hartmut M Hanauske-Abel; Deepti Saxena; Paul E Palumbo; Axel-Rainer Hanauske; Augusto D Luchessi; Tavane D Cambiaghi; Mainul Hoque; Michael Spino; Darlene D'Alliessi Gandolfi; Debra S Heller; Sukhwinder Singh; Myung Hee Park; Bernadette M Cracchiolo; Fernando Tricta; John Connelly; Anthony M Popowicz; Richard A Cone; Bart Holland; Tsafi Pe'ery; Michael B Mathews
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

Authors:  Deepti Saxena; Michael Spino; Fernando Tricta; John Connelly; Bernadette M Cracchiolo; Axel-Rainer Hanauske; Darlene D'Alliessi Gandolfi; Michael B Mathews; Jonathan Karn; Bart Holland; Myung Hee Park; Tsafi Pe'ery; Paul E Palumbo; Hartmut M Hanauske-Abel
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.